ClinicalTrials.gg
RecruitingNCT06391242Updated Nov 12, 2026

Stereotactic Body Radiotherapy vs Conventional Palliative Radiotherapy for Painful Non-Spine Bone Metastases

A Phase 3 interventional study of Standard Conventional Radiotherapy and Stereotactic Body Radiotherapy in Cancer Metastatic, sponsored by Canadian Cancer Trials Group. Recruiting at 13 sites in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Canadian Cancer Trials Group · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2025; still recruiting 1 year 8 months later.
Updated Nov 12, 20262 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
230
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 353 studies in Neoplasm Metastasis with a site in Canada — 58 open to participants now, 116 under way, 39 of them phase 3. Neoplasm Metastasis · Canada.

Planned enrollment
132nd of 323
230 · median 152
Started
2025
with 20 others
Phase 3
98 of 353
15 open now
Primary completion
2027-07
later than 60 of 115 live
Registered
318th of 353
by date

Among the 353 studies in Neoplasm Metastasis with a site in Canada, this one is the 132nd largest by planned enrollment of the 323 interventional ones that give a count, is one of 21 that started in 2025, is one of 98 in phase 3, reaches primary completion later than 60 of the 115 other live ones, and was the 318th registered.

Neoplasm Metastasis

4,052 studies on the registry are indexed under Neoplasm Metastasis; 891 are open to participants now.

Browse Neoplasm Metastasis studies →

Open to participants now

58 of the 353 studies in Neoplasm Metastasis with a site in Canada are open now. Recruiting first, the newest first:

53 more — sign in →

All 58 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 692 Neoplasm Metastasis studies recruiting now, 539 (78%) set no upper age limit and 96 (14%) stop at 75 or younger; 47 take children under 18; 18 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 353 studies in Neoplasm Metastasis with a site in Canada, or all of them as a file.
02

Study summary

This study is being done to answer the following question: Is Stereotactic Body Radiation Therapy or SBRT (a form of radiation therapy which can deliver high doses of radiation to the specific painful area of the body most affected by cancer, while keeping the radiation beams away from the healthy parts of the body that surround the cancer) better for pain relief than the standard treatment of conventional radiation therapy or CRT (a form of radiation therapy which delivers radiation to the painful area but can also negatively affect other parts of the body in the same area)

Read the detailed description

This is a multi-centre, phase III randomized controlled trial comparing SBRT to conventional palliative EBRT in patients with solid tumours and a dominant painful non-spine bone metastasis as defined by a worst pain score of 2 or greater. 230 participants will be enrolled to the study. Participants will have radiation for 5 treatments (conventional palliative EBRT 20Gy/5; SBRT 30Gy/5 or 35Gy/5) and then will be followed for pain response and radiological progression at 3 and 6 months post treatment.

03

Conditions studied

  • Cancer Metastatic

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Histologic confirmation of solid tumour.
  • Patient with a dominant painful non-spine bone and a worst minimum pain score of 2 using the BPI attributed to that dominant site
  • Expected overall survival of greater than 6 months as determined by the treating physician
  • Suitable for protocol defined SBRT and CRT.
  • Stable pain with no immediate plan to alter analgesic regimen.
  • performance status of 0-2.
  • Participant consent must be appropriately obtained in accordance with applicable local and regulatory requirements. Each participant must sign a consent form prior to enrolment in the trial to document their willingness to participate

Exclusion criteria

Exclusion Criteria:

  • of the hands, feet, cranium or spine (including sacrum) as the dominant/index pain site.
  • Bone metastasis arising from a small cell or germ cell.
  • Radionuclide therapy within 30 days of randomization.
  • Patient treated with prior palliative RT to the dominant painful bone metastasis site (prior radiation exposure is permitted if prior to development of the dominant metastasis and would not influence the applicability of either treatment arm of the current study).
  • Received systemic chemotherapy within 1 week of the protocol RT, or who are expected/planned to receive chemotherapy within one week of completing protocol RT.
  • Participants with an unstable pathologic fracture at the dominant painful bone metastasis, or for whom surgical fixation would be the preferred intervention if possible.
  • Pregnant or lactating individuals.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
230 participants (estimated)

Study arms

  • Active comparator
    Standard Conventional Radiotherapy

    Radiation: Standard Conventional Radiotherapy

  • Experimental
    Stereotactic Body Radiotherapy

    Radiation: Stereotactic Body Radiotherapy

Interventions

  • RadiationStandard Conventional Radiotherapy

    20Gy in 5 fractions

  • RadiationStereotactic Body Radiotherapy

    30 or 35Gy in 5 fractions

06

What researchers measure

Primary outcomes

  1. Complete pain response utilizing the Cochran-Mantel-Hanzeal test

    Time frame: 27 months

Secondary outcomes

  1. Pain response pattern at 3 months: partial, stable or progressive pain

    Time frame: 27 months

  2. Early (1 month post RT) and late (6 months post RT) CPR and response patterns (partial, stable, and progressive pain);

    Time frame: 27 months

  3. Re-irradiation rate within the 6-month follow-up period

    Time frame: 27 months

  4. Incidence of fracture at the radiation target site

    Time frame: 27 months

  5. Incidence of treatment-related AE rates >/- grade 2 utilizing CTCAE v5

    Time frame: 27 months

  6. Imaging-based local control rates at 3 and 6 months post-treatment

    Time frame: 27 months

  7. Patient reported outcomes utilizing EORTC QLQ-C30

    Time frame: 27 months

  8. Patient reported outcomes utilizing EORTC QLQ-BM22

    Time frame: 27 months

07

Study locations

13 of 13 sites recruiting
  • Arthur J.E. Child Comprehensive Cancer Centre
    Calgary, Alberta T2N 5G2, Canada
    Recruiting
    • Marc Kerba · Contact403 521-3164
  • BCCA - Vancouver
    Vancouver, British Columbia V5Z 4E6, Canada
    Recruiting
    • Emma Dunne · Contact604 877-6000
  • Dr. H. Bliss Murphy Cancer Centre
    St. John's, Newfoundland and Labrador A1B 3V6, Canada
    Recruiting
    • Jonathan Greenland · Contact709 777-7802
  • Juravinski Cancer Centre at Hamilton Health Sciences
    Hamilton, Ontario L8V 5C2, Canada
    Recruiting
    • Anand Swaminath · Contact905 387-9495
  • Kingston Health Sciences Centre
    Kingston, Ontario K7L 2V7, Canada
    Recruiting
    • Michael Kucharczyk · Contact
  • London Health Sciences Centre Research Inc.
    London, Ontario N6A 5W9, Canada
    Recruiting
    • Timothy Nguyen · Contact519 685-8600
  • Stronach Regional Health Centre at Southlake
    Newmarket, Ontario L3Y 2P9, Canada
    Recruiting
    • Zahra Kassam · Contact905 895-4521
  • Odette Cancer Centre
    Toronto, Ontario M4N 3M5, Canada
    Recruiting
    • Alexander Louie · Contact416 480-4951
  • University Health Network
    Toronto, Ontario M5G 2M9, Canada
    Recruiting
    • Chiaojung Jillian Tsai · Contact416 946-4501
  • Windsor Regional Cancer Centre
    Windsor, Ontario N8W 2X3, Canada
    Recruiting
    • Stephen Tran · Contact519 253-5253
  • CIUSSS de l'Est-de-I'lle-de-Montreal
    Montreal, Quebec H1T 2M4, Canada
    Recruiting
    • Peter Vavassis · Contact514 252-3425
  • CHUM-Centre Hospitalier de l'Universite de Montreal
    Montreal, Quebec H2X 3E4, Canada
    Recruiting
    • Giuseppina Laura Masucci · Contact514 890-8254
  • Hotel-Dieu de Quebec
    Québec, Quebec G1R 2J6, Canada
    Recruiting
    • Isabelle Thibault · Contact418 691-5181
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Jul 2027, 27 months after the start.

Of 55 non-industry phase 3 interventional studies under Neoplasm Metastasis, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 49 and three quarters within 108. This study's planned 27 months is below that.

Counting every sponsor, half of 138 studies reached it within 49 months; a quarter within 36 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 17, 2024
First posted
Apr 30, 2024
StartActual
Mar 7, 2025
Primary completionEst.
Jul 1, 2027
CompletionEst.
Jan 1, 2028
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites added
Show 2 added (2 Canada)
  • Windsor Regional Cancer Centre · Windsor, Canada
  • Dr. H. Bliss Murphy Cancer Centre · St. John's, Canada
across 2 updates, Oct 16, 2026 – Nov 12, 2026
Show all 2 updates
  1. Nov 12, 2026
    1 site added
    Show site
    • Dr. H. Bliss Murphy Cancer Centre · St. John's, Canada
  2. Oct 16, 2026
    1 site added
    Show site
    • Windsor Regional Cancer Centre · Windsor, Canada
    + 2 other changes: verification date and responsible party

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06391242
Lead sponsor
Canadian Cancer Trials Group
Collaborators
Trans Tasman Radiation Oncology Group
Responsible party
Sponsor
First posted
Apr 30, 2024
Start date
Mar 7, 2025
Primary completion
Jul 1, 2027 (estimated)
Completion
Jan 1, 2028 (estimated)
Last update
Nov 12, 2026

Study contacts

Wendy Parulekar
Contact
wparulekar@ctg.queensu.ca
613-533-6430
Arjun Sahgal
study chair · Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON, Canada
Tim Nguyen
study chair · London Regional Cancer Program, London, ON, Canada

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion